Cargando…
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300180/ https://www.ncbi.nlm.nih.gov/pubmed/28182783 http://dx.doi.org/10.1371/journal.pone.0172184 |
| _version_ | 1782506140846784512 |
|---|---|
| author | Troya, Jesús Ryan, Pablo Ribera, Esteban Podzamczer, Daniel Hontañón, Victor Terrón, Jose Alberto Boix, Vicente Moreno, Santiago Barrufet, Pilar Castaño, Manuel Carrero, Ana Galindo, María José Suárez-Lozano, Ignacio Knobel, Hernando Raffo, Miguel Solís, Javier Yllescas, María Esteban, Herminia González-García, Juan Berenguer, Juan Imaz, Arkaitz |
| author_facet | Troya, Jesús Ryan, Pablo Ribera, Esteban Podzamczer, Daniel Hontañón, Victor Terrón, Jose Alberto Boix, Vicente Moreno, Santiago Barrufet, Pilar Castaño, Manuel Carrero, Ana Galindo, María José Suárez-Lozano, Ignacio Knobel, Hernando Raffo, Miguel Solís, Javier Yllescas, María Esteban, Herminia González-García, Juan Berenguer, Juan Imaz, Arkaitz |
| author_sort | Troya, Jesús |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5300180 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-53001802017-02-28 Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study Troya, Jesús Ryan, Pablo Ribera, Esteban Podzamczer, Daniel Hontañón, Victor Terrón, Jose Alberto Boix, Vicente Moreno, Santiago Barrufet, Pilar Castaño, Manuel Carrero, Ana Galindo, María José Suárez-Lozano, Ignacio Knobel, Hernando Raffo, Miguel Solís, Javier Yllescas, María Esteban, Herminia González-García, Juan Berenguer, Juan Imaz, Arkaitz PLoS One Correction Public Library of Science 2017-02-09 /pmc/articles/PMC5300180/ /pubmed/28182783 http://dx.doi.org/10.1371/journal.pone.0172184 Text en © 2017 Troya et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Troya, Jesús Ryan, Pablo Ribera, Esteban Podzamczer, Daniel Hontañón, Victor Terrón, Jose Alberto Boix, Vicente Moreno, Santiago Barrufet, Pilar Castaño, Manuel Carrero, Ana Galindo, María José Suárez-Lozano, Ignacio Knobel, Hernando Raffo, Miguel Solís, Javier Yllescas, María Esteban, Herminia González-García, Juan Berenguer, Juan Imaz, Arkaitz Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study |
| title | Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study |
| title_full | Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study |
| title_fullStr | Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study |
| title_full_unstemmed | Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study |
| title_short | Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study |
| title_sort | correction: abacavir/lamivudine plus rilpivirine is an effective and safe strategy for hiv-1 suppressed patients: 48 week results of the simriki retrospective study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300180/ https://www.ncbi.nlm.nih.gov/pubmed/28182783 http://dx.doi.org/10.1371/journal.pone.0172184 |
| work_keys_str_mv | AT troyajesus correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT ryanpablo correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT riberaesteban correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT podzamczerdaniel correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT hontanonvictor correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT terronjosealberto correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT boixvicente correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT morenosantiago correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT barrufetpilar correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT castanomanuel correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT carreroana correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT galindomariajose correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT suarezlozanoignacio correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT knobelhernando correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT raffomiguel correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT solisjavier correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT yllescasmaria correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT estebanherminia correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT gonzalezgarciajuan correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT berenguerjuan correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT imazarkaitz correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy AT correctionabacavirlamivudineplusrilpivirineisaneffectiveandsafestrategyforhiv1suppressedpatients48weekresultsofthesimrikiretrospectivestudy |